Search

Among the challenges posed by the COVID-19 pandemic, significant efforts have been undertaken to develop antimicrobial/antiviral surfaces by exploiting coating solutions. In this article, we review the actions undertaken by the EU project MIRIA, the main one being the reduction of pathogen transmission on high-traffic surfaces in public and healthcare environments. The project implements several synergies from key antimicrobial/antiviral element selection to the grafting of complex-shaped surfaces. The focus is given to one of the project's key strategies: the adoption of sol-gel technology, known for its efficiency in creating versatile, cost-effective coatings suitable for a wide range of substrates. The project rigorously tests the coatings in simulated environments, such as operating theatres, ensuring their effectiveness and safety. This includes comprehensive durability testing against environmental, chemical, and mechanical stresses, guaranteeing the coatings' long-term functionality. MIRIA's validation process encompasses antibacterial, antifungal, and antiviral testing in line with international standards, confirming their broad-spectrum pathogen resistance. Along with this overview, the impact of the initiative is elucidated, extending beyond healthcare, enhancing public health, creating safer living, and working environments, and reducing economic losses due to illness. To this, the MIRIA project is expected to significantly contribute to the European research and innovation in antimicrobial coatings, addressing challenges like scalability and efficacy against various pathogens. The emphasis on sustainable synthesis, including bio-based materials which align with ecological goals, positions MIRIA as a pivotal initiative in enhancing health safety standards and resilience across Europe. Highlights: The MIRIA project goal is to avoid cross contamination in high traffic objects in the health field. The strategy is the development of 99.99% effective antimicrobial nanocoatings. MIRIA makes use of sol-gel for its versatility on multiple surfaces and on-site application. Standardized testing will ensure non-toxic, antimicrobial and durability properties. One of the pathogens considered is COVID-19, to enhance readiness for future pandemics. [ABSTRACT FROM AUTHOR]

The rarity of malignant and intermediate vascular tumors in children means that little is known about their clinical course, optimal treatment, and variables predicting survival. A total of 32 children with malignant vascular tumors (14 angiosarcomas [AS], 5 epithelioid hemangioendotheliomas, and 13 intermediate vascular tumors, including other hemangioendotheliomas plus adult-type hemangiopericytomas), registered in the German and Polish Paediatric Soft Tissue Sarcomas Study Groups, were treated following the Cooperative Weichteilsarkom Studiengruppe (CWS)-81, -86, -91, and -96 protocols. Male sex, AS histology, tumor size >5 cm, and T2 invasiveness were independent predictors of inferior 5-year overall survival, while AS histology and T2 invasiveness were predictors of inferior 5-year event-free survival. AS histology was the most important negative prognostic factor for overall survival and event-free survival. Completeness of primary tumor excision was a good prognostic factor for survival in univariate, but not multivariate, analysis. Local therapy (radiotherapy and delayed surgery) were provided to the minority of patients (28% and 38%, respectively) late in the course of disease (after a mean of 9 and 6 months, respectively) and did not prevent local relapses. Response to systemic treatment was poor (44%) and did not prevent local and distant relapses. The clinical course and outcome in childhood epithelioid HE seems to be similar to intravascular tumors and less aggressive than AS. RTX and delayed surgery should be performed more frequently and earlier in the disease course. An urgent need for modification of systemic therapy is needed because of the development of many metastatic and/or combined relapses and poor response to classic chemotherapy. The problem of effective therapy for childhood AS is the most appaling: 13 of 14 patients died of progression despite multimodal treatment. [ABSTRACT FROM AUTHOR]

Comparative assessment of the HRQL of paediatric survivors of brain tumours (BT) and of acute leukaemia against a population of their healthy peers. The study consisted of patients who had completed treatment for BT ( n = 36) or acute leukaemia ( n = 35) and were aged between 8 and 19. Healthy children ( n = 60) were selected from among pupils of schools. HRQL was evaluated directly and indirectly on the basis of the Polish language version of the PedsQL™ 4.0 Generic Core scales. The influence of selected factors (sex, age, time from the end of treatment and type of treatment) on the HRQL result was analysed. In all the aspects analysed (total, physical, psychosocial, emotional, social and school functioning), the HRQL of BT and leukaemia survivors was significantly lower in comparison to their healthy peers. The HRQL of patients after BT treatment was also significantly lower than that of the survivors of leukaemia. The parent-proxy reported HRQL was consistent with the children’s self-assessment. Patients treated with radiotherapy presented a significantly lower evaluation of life quality in the physical sphere. Evaluation of HRQL should be treated as an additional independent parameter in an assessment of the long-term results of oncological treatment. [ABSTRACT FROM AUTHOR]

Cellular resistance in childhood acute leukemias might be related to profile and function of multidrug resistance proteins and apoptosis regulating proteins. The aims of the study were: (1) analysis of expression of MRP1, PGP1, LRP, BCL-2 and p53 proteins; (2) correlation with ex vivo drug resistance, and (3) analysis of their prognostic impact on clinical outcome in childhood acute lymphoblastic (ALL) and acute myeloid (AML) leukemia. Total number of 787 children diagnosed for initial ALL ( n = 527), relapsed ALL ( n = 104), initial AML ( n = 133) and relapsed AML ( n = 23) were included into the study. Mean follow-up period was 3.5 years. Drug resistance for up to 30 anticancer agents was performed by the MTT assay. Expression of all proteins was tested by flow cytometry. Both initial AML and relapsed ALL samples showed higher drug resistance than initial ALL samples. No significant differences were found in drug resistance between initial and relapsed AML samples. The presence of multidrug resistance and apoptosis proteins had no impact on pDFS in iALL and iAML, however strong trend towards adverse prognostic impact of MRP1, PGP and LRP on pDFS in rALL was observed. The same trend was observed for each of analyzed co-expressions of tested multidrug resistance proteins. The phenomenon of cellular drug resistance in childhood acute leukemias is multifactorial and plays an important role in response to therapy. Expression of MRP1, PGP and LRP proteins, as well as their co-expression play possible role in childhood relapsed ALL. [ABSTRACT FROM AUTHOR]